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Abstract
In human tumors, changes in the surface expression and/
or function of major histocompatibility complex (MHC)
class I antigens are frequently found and may provide
malignant cells with a mechanism to escape control of
the immune system. This altered human lymphocyte
antigen (HLA) class I phenotype can be caused by ei-
ther structural alterations or dysregulation of genes
encoding subunits of HLA class I antigens and/or com-
ponents of the MHC class I antigen-processing ma-
chinery (APM). Herein we analyze the expression of
several proteins involved in the generation of MHC
class I epitopes in feline injection site sarcoma, a spon-
taneously occurring tumor in cats that is an informa-
tive model for the study of tumor biology in other species,
including humans. Eighteen surgically removed primary
fibrosarcoma lesions were analyzed, and an enhanced
expression of two catalytic subunits of immunopro-
teasomes, PA28 and leucine aminopeptidase, was found
in tumors compared to matched normal tissues. As
a functional counterpart of these changes in protein
levels, proteasomal activities were increased in tissue
extracts from fibrosarcomas. Taken together, these re-
sults suggest that alterations in the APM system may
account for reduced processing of selected tumor
antigens and may potentially provide neoplastic fibro-
blasts with a mechanism for escape from T-cell rec-
ognition and destruction.
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Introduction
The immune system continually screens for viral infections
and cancers by monitoring whether cells are synthesizing
foreign or mutant proteins [1]. The surveillance process de-
pends on the presence of major histocompatibility complex
(MHC) class I molecules that bind to and display cytotoxic
T lymphocyte (CTL) peptides (known as antigenic peptides
or epitopes) that are derived from the entire spectrum of
proteins expressed in the cell. Under normal physiological
conditions, all MHC class I–presented peptides are derived
from normal autologous sequences to which the immune
system is nonreactive, owing to self-tolerance. However, if the
cell is infected by viruses or expresses mutant gene products
(e.g., oncogene products), then nonnative (‘‘foreign’’) peptides
will be displayed and will stimulate CD8+ lymphocytes (CTL) to
kill the anomalous cell. Furthermore, CTL can also be activated
by self-peptide–MHC class I complexes expressed at supraphys-
iological levels [2]. At present, there is a general agreement
that the immune system can recognize and destroy nascent
transformed cells, thereby preventing tumor formation [3,4].
The majority of antigenic peptides are generated during
the degradation of intracellular proteins by the ubiquitin–
proteasome pathway [1]. These peptides are then translocated
through the TAP transporter into the endoplasmic reticulum,
where they bind to MHC class I heterodimers. This binding sta-
bilizes the interaction between MHC class I heavy and light
chains and allows the heterodimer to be transported to the cell
surface. The active form of the proteasome, which appears
to degrade most cellular proteins, is 26S proteasome [5]. This
2.4-MDa complex is formed by the association of a 19S-
regulatory particle with one or both ends of the core 20S pro-
teasome. The 26S proteasome degrades ubiquitinated and
some nonubiquitinated proteins in an ATP-dependent manner
[6]. Proteins are cleaved within the 20S (700 kDa) core pro-
teasome, which is composed of four stacked rings. The two
inner b-rings contain six proteolytic sites that differ in substrate
specificity: two have chymotrypsin-like activities, two have
trypsin-like activities, and two possess caspase-like activities.
The immune system has evolved several mechanisms
to modify the activity of the ubiquitin–proteasome pathway
and to enhance the efficiency of the generation of MHC class
I–presented peptides [1]. Several components of this system
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are induced by the immune modifier interferon-g (IFN-g),
including special forms of the proteasome, termed immuno-
proteasomes, that contain novel active subunits, the a and b
subunits of the proteasome activator PA28 [7], and leucine
aminopeptidase (LAP) [8], a cytosolic enzyme that can
generate antigenic peptides from longer proteasome prod-
ucts but also destroy them [9–12]. Each IFN-g–inducible
proteasomal b subunit is homologous with a constitutive cat-
alytic subunit (LMP2/Y, LMP7/X, and MECL/Z) and can re-
place its homologue during proteasome assembly.
It has been well established that the presence of these
IFN-g– induced subunits alters catalytic activity against
model peptide substrates. They enhance cleavages after
hydrophobic, basic, and branched-chain residues, while sup-
pressing cleavages after acidic residues. Therefore, immu-
noproteasomes generate a different spectrum of oligopeptide
products compared to constitutive particles. This new pattern
of peptides has been proposed to promote antigen presenta-
tion [1] because the transporter associated with antigen pre-
sentation (TAP) and MHC class I molecules strongly prefer
to bind peptides with carboxyl-terminal hydrophobic and
basic residues over acidic ones. In addition, this altered spec-
ificity may also enhance the production of N-extended pre-
cursors of antigenic peptides [13] that are trimmed to the
presented epitopes by aminopeptidases in the cytosol or en-
doplasmic reticulum [14]. Another IFN-g–inducible compo-
nent of the proteasome system that affects antigen presentation
is PA28 (also termed REG or 11S), a ring-shaped 180-kDa
multimeric complex that can bind to the free ends of 20S or
asymmetric (i.d. 19S–20S) 26S proteasomes and dramatically
enhance their ability to degrade short peptide substrates [7].
Expression of PA28a or PA28a/b has been reported to enhance
the MHC class I antigen presentation of some, but not all, epi-
topes [1], and so-called ‘‘hybrid proteasomes’’ (i.d. 19S–20S–
PA28) have been shown to generate a different set of peptide
products from proteins [15]. Therefore, by increasing the variety
of peptides generated from a protein substrate, PA28 can pre-
sumably enhance the diversity of epitopes presented on the
cell surface and thereby increase the possibility that an appro-
priate CTL response is elicited. Nevertheless, in contrast to
the current view that immunoproteasomes are always better
suited for the processing of MHC class I–restricted peptides,
it has been shown that several tumor-specific antigens and
melanoma differentiation antigens, which are efficiently pro-
duced by standard proteasomes, are poorly produced by im-
munoproteasomes [16–18]. Therefore, a switch from normal
proteasomes to immunoproteasomes may be one of the mech-
anisms that allow tumor cells to escape attack from CTLs [19].
So far, however, studies using cultured tumor cell lines,
antigen-processing mutants, and surgically removed malig-
nant lesions have demonstrated a reduced expression of
IFN-g– induced proteasome and PA28 subunits [20–26].
These abnormalities correlate with impaired processing of
antigenic peptides, low levels or loss of MHC class I surface
expression, and resistance to CTL-mediated lysis [20]. Fur-
thermore, deficiencies in the antigen-processing machinery
(APM) can be reverted by cytokine treatment, particularly by
IFN-g [21,25]. As only a limited number of studies on alter-
ations of APM components have been performed in surgi-
cally removed tumor lesions, we analyzed feline injection site
sarcoma (FISS), a spontaneously occurring, highly locally
invasive tumor that develops at the site of injection of
vaccines or other drugs in cats [27]. Histologically, FISS is
a mesenchymal tumor (usually well differentiated) that is
characterized by plumps of spindle cells arranged in inter-
woven bundles with anaplastic tendency, with cells of vari-
able size and shape, pleomorphic nuclei, and an increased
number of multinucleated cells [28]. This tumor was chosen
because it represents a good informative model for carcino-
genesis and genetic susceptibility that is applicable to cancer
in all species, including humans [29,30]. In our study, we an-
alyzed 18 surgically removed primary lesions, and we found
an enhanced expression of different catalytic b subunits of
immunoproteasomes, a and b subunits of PA28, and LAP in
tumors compared to matched normal tissues. As a func-
tional counterpart of these changes in protein levels, protea-
somal cleavage specificities are modified in tissue extracts
from fibrosarcomas. Altogether, the alterations in the APM
system that we have identified might account for a reduced
processing of some tumor antigens and might potentially
provide neoplastic fibroblasts with a mechanism to escape
from T-cell recognition and destruction.
Materials and Methods
Total Proteins
Samples of fibrosarcoma and healthy subcutis were
collected from the same animal during surgery, placed on
ice, and immediately homogenized in ice-cold extraction
buffer (50 mM Tris–HCl pH 7.5, 1 mM dithiothreitol, 250 mM
sucrose, 5 mM MgCl2, 0.5 mM EDTA, and 2 mM ATP) using
an Ultraturax DIAX900 homogenizer (Heidolph Instruments,
Kelheim, Germany) and centrifuged at 14,000 rpm for 20 min-
utes at 4jC. The protein concentration in supernatants was
determined using the QUICK START Bradford Dye Reagent
1 (Bio-Rad Laboratories, Hercules, CA) using a standard
curve constructed with bovine serum albumin (BSA). Samples
were stored at 80jC until use.
Proteasome Activity Assays
Peptidase activities of proteasomes were assayed by
monitoring the production of 7-amino-4-methylcoumarin
(AMC) from fluorogenic peptides, as previously described
[13]. Briefly, Suc-LLVY-AMC (for chymotrypsin-like activity)
and Z-YVAD-AMC (for caspase-like activity) (BACHEM,
Bubendorf, Switzerland) were used at a final concentration
of 100 mM in 20 mM Tris–HCl pH 7.5, 1 mM ATP, 2 mM
MgCl2, and 0.2% BSA. Reactions were started by adding an
aliquot of tissue extracts, and the fluorescence of released
AMC (excitation, 380 nm; emission, 460 nm) was monitored
continuously at 37jC with a Carry Eclipse spectrofluorimeter
(VARIAN, Palo Alto, CA). Background activity (caused by
nonproteasomal degradation) was determined by the addi-
tion of the proteasome inhibitor MG132 (BACHEM) at a final
concentration of 10 mM.
MHC Class I APM Alterations in Cancer Cerruti et al. 961
Neoplasia . Vol. 9, No. 11, 2007
Immunoblot Analyses
Immunoblot analyses of the proteasomal and immuno-
proteasomal catalytic b subunits, PA28a/b, and LAP in both
fibrosarcomas and normal subcutis tissue extracts were per-
formed as previously described [15]. Briefly, 60 mg of total
proteins for X, Y, LMP2, and LMP7, and 40 mg for PA28a,
PA28b, and LAP were separated on a 12% SDS-PAGE gel,
and proteins were transferred on a Hybond-P membrane
(Amersham Pharmacia, Buckinghamshire, UK). Membranes
were stained with Ponceau red before incubation with the
primary antibody to confirm that similar amounts of proteins
had been transferred. The membrane was then incubated in
a blocking buffer (5% nonfat milk in 1 PBS; 0.1% Tween-20),
followed by incubation with rabbit antisera against LMP2,
LMP7, PA28a, and PA28b (a kind gift of Dr. K. Tanaka, Tokyo
Metropolitan Institute of Medical Science, Tokyo, Japan), X
(a kind gift of Prof. A. L. Goldberg, Harvard Medical School,
Boston, MA), and LAP (a kind gift of Dr. T. Saric, University of
Cologne, Cologne, Germany), and mouse monoclonal anti-Y
(a kind gift of Prof. A. L. Goldberg). Bound antibodies were
visualized using the ECL technique (ECLPlus Western Blot-
ting Detection Reagents; Amersham Pharmacia), and den-
sitometric analysis of bands was performed with a VersaDoc
1000 Imaging System (Bio-Rad Laboratories) using the
Quantity One software (Bio-Rad Laboratories).
Statistical Analysis
Because the Shapiro-Wilk test has proven that densito-
metric data were not normally distributed (data not shown),
nonparametric Wilcoxon test was performed to establish
whether protein expression levels significantly differed be-
tween fibrosarcomas and related healthy subcutis. For this
purpose, values were transformed into log10(densitometric
value + 1), and the ratio was expressed as log10(fibrosar-
coma/healthy subcutis protein expression). Furthermore,
Wilcoxon test was also used to establish whether chymo-
trypsin-like and caspase-like activities differed significantly
between fibrosarcomas and healthy subcutis. P < .05 was
considered statistically significant, whereas P < .01 was
considered highly significant. Data were graphically visual-
ized using box plots.
Immunohistochemistry
Immunohistochemistry studies were performed with the
same antibodies used for Western blot analysis. Tissue
sections (3 mm) were dewaxed in xylene, rehydrated in
graded ethanol, and washed with PBS (pH 7.0, 1 mM).
Endogenous peroxidase activity was quenched by immer-
sion in a solution of 3% hydrogen peroxide in methanol,
followed by several rinses in PBS. Nonspecific binding was
blocked by incubation with 5% BSA in PBS. Slides were then
incubated for 60 minutes at room temperature with primary
antibody, rinsed in PBS, and incubated with secondary
antibody using the Super Sensitive IHC Detection System
(BioGenex, San Ramon, CA). Slides were rinsed in PBS and
then stained with the DAKO Cytomation Liquid DAB Sub-
strate Chromogen System (DAKO Corp., Carpinteria, CA).
Sections were counterstained with Mayer’s hematoxylin
solution. Negative controls were run in parallel, replacing
the primary antibody with PBS containing 5% BSA. Tissue
sections were evaluated by light microscopy to determine
anti–X, Y, LMP7, LMP2, PA28a, PA28b, and LAP positivity.
Positive cells were counted in 10 high-power fields (400)
for each tissue section, and at least 1000 cells for each anti-
gen were evaluated. The number of cells positive for each
antigen was estimated semiquantitatively and was scored as
() absence of immunoreaction; (+) 1% to 10% positive cells;
(++) 11% to 50% positive cells; (+++) > 50% positive cells.
Results
Patients and Tissue Samples
Eighteen fibrosarcoma lesions and matched normal sub-
cutis were obtained from 11 male and 7 female cats with
an average age of 10.6 years (range, 5–16 years; median,
10.5 years), which had undergone wide-margin surgery at
the Veterinary Teaching Hospital of Turin University. For 17
patients, complete follow-up, in terms of both disease-free
survival time and overall survival time, was available. Eleven
tumors were located in the subcutis of the interscapular re-
gion, three were located on the dorsal neck, one was lo-
cated on the left scapula, one was located on the right scapula,
and two were located on the thorax wall. Fourteen were pri-
mary lesions, and four were local recurrences. Histologic ex-
amination revealed that all lesions were fibrosarcomas. None
of the patients had received any preoperative treatment such
as chemotherapy, radiotherapy, or immunotherapy. Tumor
staging was based on the more recent World Health Organi-
zation Tumor–Node–Metastasis (TNM) classification system
[31]. One tumor was classified as T1N0M0, four were classified
as T2N0M0, six were classified as T3N0M0, and seven were
classified as T4N0M0. The characteristics of each tumor are
reported in Table 1.
Enhanced LMP2 and LMP7 and Unchanged X and Y
Expressions in Fibrosarcoma Lesions
Abnormalities in several components of class I APM are
often associated with neoplastic transformation and may
confer a nonimmunogenic phenotype to tumor cells [3,4,32].
In particular, a reduced expression of proteasomal subunits is
the most frequent alteration described in several cell lines
of neoplastic origin or in naturally occurring tumors [20–26].
Therefore, to determine the expression levels of proteasomal
and immunoproteasomal catalytic b subunits, tissue extracts
from 18 surgically removed fibrosarcoma lesions and matched
healthy subcutis were analyzed by Western blot analysis using
antibodies specific for X, Y, LMP2, and LMP7 subunits. This
analysis showed (Figure 1A) unchanged expression of X and
Y in the neoplastic component compared to corresponding
healthy subcutis in all cases evaluated. Densitometric anal-
ysis of specific bands revealed an identical expression
pattern of these two catalytic proteasomal subunits in both
healthy and normal tissues (Figure 1B) (X: Z = 0.457, P =
.647; Y: Z = 2.570, P = .10; Wilcoxon test). On the contrary,
expression of the IFN-g–induced catalytic subunits LMP2
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Table 1. Characteristics of Fibrosarcoma Tumors Analyzed.
Number Age
(years)








1 9 M Left scapula Primary tumor Dead T1N0M0 537 628
2 11 M Interscapular Local recurrence Dead T2N0M0 988 1588
3 9 F Interscapular Primary tumor Alive T2N0M0 971 971
4 13 F Neck Primary tumor Alive T2N0M0 1023 1023
5 13 F Thorax Local recurrence LFU T2N0M0 248 248
6 13 M Interscapular Primary tumor LFU T3N0M0 158 158
7 11 M Neck Primary tumor LFU T3N0M0 315 315
8 10 F Interscapular Primary tumor Alive T3N0M0 914 914
9 10 F Interscapular + neck Primary tumor LFU T3N0M0 440 440
10 5 F Interscapular Primary tumor Alive T3N0M0 758 758
11 10 M Interscapular Primary tumor Dead T3N0M0 481 481
12 10 M Interscapular Primary tumor Dead T4N0M0 459 459
13 12 M Interscapular Primary tumor Alive T4N0M0 1247 1247
14 7 M Interscapular Primary tumor Alive T4N0M0 1401 1401
15 16 F Right scapula Local recurrence Dead T4N0M0 2121 2243
16 13 M Neck Primary tumor Dead T4N0M0 0 0
17 6 M Lateral thorax Local recurrence LFU T4N0M0 476 476
18 12 M Interscapular Primary tumor Dead T4N0M0 221 281
F, female; M, male; LFU, lost to follow-up.
*On July 25, 2007.
Figure 1. Levels of proteasomal (X and Y) and immunoproteasomal (LMP2 and LMP7) catalytic  subunits in fibrosarcomas and healthy control subcutis. Eighteen
specimens were analyzed. Two representative Western blot analyses for X and Y (A) and two representative Western blot analyses for LMP2 and LMP7 (C) are shown.
Expression ratios of X and Y (B) and of LMP2 and LMP7 (D) in fibrosarcomas and healthy subcutis were calculated as reported in Materials and Methods. It is worthy of
note that the intensities of bands can only be compared within each single experiment and not between them, as blots were performed with different antibodies.
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and LMP7 was highly enhanced in tumor lesions compared
to matched healthy tissues (Figure 1, C and D). Statistical
analysis of densitometric data demonstrated that these
differences are highly significant (LMP2: Z = 3.724, P =
.0002; LMP7: Z = 3.724, P = .0002; Wilcoxon test) but not
significantly correlated to tumor stage or clinical outcome
(data not shown). Taken together, these results clearly dem-
onstrate that, compared to healthy subcutis, fibrosarcomas
have no differences in the expression levels of two catalytic
subunits (X and Y) of constitutive proteasomes, whereas
two catalytic subunits (LMP2 and LMP7) of immunoprotea-
somes are strongly induced.
Enhanced Expression of PA28a/ and LAP
in Fibrosarcomas
It has been well established that other components of
APM collaborate with proteasomes in generating the final
versions of epitopes that are presented on the cell surface in
association with MHC class I molecules [1]. Specifically, the
proteasome activator PA28 has been reported to enhance
the generation of several class I epitopes [7], whereas LAP
is one of the main enzymes involved in the cytosolic trimming
of both epitopes and their N-extended precursors [9–12],
which represent major proteasomal products and whose
generation is further enhanced by immunoproteasomes [13].
Therefore, we analyzed the expression of the a and b sub-
units of PA28 and LAP in fibrosarcomas. Interestingly, West-
ern blot analysis showed that expression levels of PA28a/b
are much higher in fibrosarcomas compared to healthy con-
trol subcutis (Figure 2A) and that these differences are highly
significant (Figure 2B) (PA28a: Z =3.724, P = .0002; PA28b:
Z = 3.724, P = .0002; Wilcoxon test). Additionally, LAP ex-
pression was enhanced in fibrosarcomas compared to con-
trol subcutis, although to a lesser extent (Figure 2, C and D)
(LAP: Z = 3.549, P = .0004; Wilcoxon test). Finally, the en-
hanced expression of these IFN-g–induced APM compo-
nents is not significantly correlated with tumor stage or course
of the disease (data not shown).
Taken together, these results demonstrate that PA28a/b
and LAP, three important components of the APM strongly
induced by IFN-g, are expressed at significantly higher levels
in fibrosarcomas than in healthy subcutis.
Enhanced Proteasomal Activity in Fibrosarcomas
To investigate whether differences in the expression
levels of proteasomal and PA28 subunits detected by West-
ern blot analysis correlated with changes in enzymatic
activity, we next analyzed the cleavage specificity of pro-
teasomes in homogenates of fibrosarcomas and healthy
subcutis. In agreement with our data showing an enhanced
expression of two proteasomal catalytic subunits and PA28,
chymotrypsin-like activity, the main proteasomal proteolytic
activity that is rate-limiting in protein degradation, is nearly
18-fold higher in fibrosarcomas than in healthy subcutis
(Table 2 and Figure 3A) (Z = 3.724, P = .0002; Wilcoxon
test). Additionally, caspase-like activity was significantly en-
hanced in fibrosarcomas, albeit to a lesser extent (Table 2
and Figure 3B) (Z = 3.724, P = .0002; Wilcoxon test).
Together, these results demonstrate that, in agreement with
an enhanced expression of IFN-g–induced proteasomal cat-
alytic b subunits and PA28, chymotrypsin-like and caspase-
like activities of proteasomes are also highly increased in
extracts from fibrosarcomas.
Immunohistochemical Analysis
To investigate the expression of APM components at the
single-cell level, two formalin-fixed paraffin-embedded sur-
gically removed fibrosarcoma lesions and related healthy
subcutis were immunohistochemically analyzed for the ex-
pression of X, Y, LMP2, LMP7, PA28a, PA28b, and LAP
(Figure 4 and Table 3). This analysis demonstrated that all
these proteins are expressed in neoplastic fibroblasts, al-
though to different extents. In particular, the number of cells
that are positive for LMP2, LMP7, PA28a, PA28b, and LAP is
higher than that for X and Y (Table 3). On the contrary, in
normal fibroblasts of the same animals, PA28b is undetect-
able, whereas the other immunoproteasomal subunits are
expressed at lower levels than the subunits of constitutive
proteasomes (Table 3). Furthermore, a comparison between
neoplastic and healthy tissues revealed an equal expression
of constitutive proteasomal catalytic subunits X and Y, but a
higher expression of LMP2, LMP7, PA28a, PA28b, and LAP
in transformed than in normal fibroblasts (Table 3). There-
fore, immunohistochemical analysis clearly confirms West-
ern blot analysis results showing an enhanced expression of
IFN-g–induced APM elements in neoplastic fibroblasts.
Discussion
Previous reports have suggested that defects in the produc-
tion of antigenic peptides for MHC class I assembly and
presentation might contribute to the immune escape of tumor
cells [3,4,32]. To test this hypothesis, we measured the
expression levels of several components of APM in FISS,
a locally invasive and histologically aggressive soft-tissue
sarcoma that develops at the site of injection administration
[27] and that represents a highly informative model for the
study of tumor biology in different species, including humans
[29,30]. Moreover, to investigate whether differences in
protein expression correlate with differences in enzymatic
activity, we analyzed the cleavage specificity of proteasomes
in homogenates of fibrosarcomas and healthy subcutis.
The results of the present study can be summarized as
follows: 1) proteasomal catalytic b subunits X and Y are ex-
pressed roughly at the same levels in fibrosarcoma lesions
and healthy subcutis; 2) immunoproteasome catalytic b
subunits LMP2 and LMP7, a and b subunits of the protea-
some activator PA28, and LAP are expressed at much higher
levels in fibrosarcomas than in normal subcutis; and 3) tissue
extracts from fibrosarcomas present enhanced proteasomal
chymotrypsin-like activities and, to a lesser extent, caspase-
like activities than healthy subcutis.
In tumors, abnormalities in the expression and/or function
of the components of class I APM such as tapasin, TAP, LMP,
and PA28 subunits [20,21] may cause a marked downregu-
lation of the cell surface expression of MHC class I antigens,
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thereby providing malignant cells with a mechanism to
escape control of the immune system [33,34]. Such abnor-
malities are frequently found in malignant cells in both
humans andmice, and represent a major obstacle to the suc-
cessful implementation of T-cell–based immunotherapy.
Furthermore, loss of the ability to process immunodominant
tumor antigens represents an additional mechanism by
which tumor cells can escape immune recognition [4,19,32].
To date, the expression of proteasomal and PA28 subunits
has been investigated only in a limited number of surgically
removed lesions and tumor cell lines of distinct histology
from humans, whereas no data are available on the tumoral
expression of LAP, a cytosolic enzyme that can generate
antigenic peptides from longer proteasome products but also
destroy them [9–12]. Although some discrepancies are
present in previous studies, which probably reflect differ-
ences in the tumors or cell lines analyzed and/or in the
methods used to detect changes in class I peptide–generating
machinery, the overall picture that arises is that a general
Figure 2. Expression of PA28a/ and LAP in 18 fibrosarcomas and healthy control subcutis. (A) Two representative Western blot analyses for PA28a and two
representative Western blot analyses for PA28 are shown. (B) Box plots of the expression ratios of PA28a/ between fibrosarcomas and healthy subcutis,
determined as reported in Materials and Methods. *Nonspecific band. (C) Two representative Western blot analyses for LAP are shown. (D) Box plots of the
expression ratios of LAP between fibrosarcomas and healthy subcutis.
Table 2. Chymotrypsin-Like and Caspase-Like Activities in Fibrosarcoma
Lesions and Related Healthy Subcutis.
Healthy Subcutis Fibrosarcomas
Chymotrypsin-like activity











Data are presented as the mean ± SEM (median) of the specific activities of
all 18 animals analyzed.
SEM, standard error of the mean.
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Figure 3. Increase in proteasomal chymotrypsin-like activity (A) and caspase-like activity (B) in tissue extracts from 18 fibrosarcomas compared to healthy subcutis.
Figure 4. Immunohistochemical detection of different MHC class I antigen-processing components in two different fibrosarcomas. Original magnification, 600.
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downregulation of IFN-g–induced proteasomal subunits is
associated with malignant transformation of cells. In this con-
text, the impaired expression of LMPs and PA28 might
cause reduced generation and presentation of some tumor-
associated antigens and therefore provide malignant cells
with a mechanism to evade control of the immune system. It
was thus unexpected that the expression of several IFN-g–
induced proteasomal components (LMP2, LMP7, PA28a, and
PA28b) is highly enhanced compared to normal autologous
tissues in FISS. Although we could not directly measure the
expression of the third catalytic proteasomal b subunits Z and
of its IFN-g–induced homologue MECL-1 due to lack of cross
reactivity for cat proteins of all the antibodies we tested,
however, our data are consistent with an enhanced expres-
sion of immunoproteasomes in FISS. In fact, incorporation of
constitutive (X, Y, and Z) or IFN-g–induced (LMP2, LMP7,
and MECL1) subunits into nascent proteasomal particles is a
cooperative process that favors only the assembly of homo-
geneous proteasomes or immunoproteasomes [35–37].
The molecular mechanisms underlying this upregulation
in fibrosarcomas lesions are presently unknown. An enhanced
expression of LMP2, LMP7, and other IFN-g–regulated
components may be a direct consequence of malignant trans-
formation, possibly modulated by overexpression of PML and
CIITA transcription factors [38,39]; alternatively, it may be
caused by high local levels of proinflammatory cytokines
such as IFN-a and IFN-g at the tumor site. In fact, although
histologic evaluation has demonstrated a limited presence
of lymphocytes, which never exceeds 5% of the total cells in
the specimens used in our study (data not shown), it is likely
that the inflammatory component present in fibrosarcomas is
still responsible for the maintenance of high local levels of
cytokines in the neoplastic lesion. Accordingly, chronic inflam-
mation is recognized as one of the possible causes of these
tumors [40] developing in a microenvironment characterized
by high levels of cytokines that are potent inducers of the im-
munoproteasomes PA28 and LAP [1]. We are currently ex-
ploring these different possibilities. Interestingly, an enhanced
expression of immunoproteasomes in FISS is not accompa-
nied by a reduction in constitutive proteasomes. This obser-
vation further suggests that neoplastic transformation in this
tumor is associated with dysregulation of mechanisms that
control proteasome subunits expression. Furthermore, our
findings are consistent with previous reports showing that
levels of proteasomal constitutive subunits are not negatively
regulated by IFN-g in several cell lines [41–43]. It is, however,
clear that incorporation of IFN-g–induced subunits into pro-
teasomes causes differences in enzymatic activities and
cleavage specificities, leading to the production of a different
set of antigenic peptides during hydrolysis of endogenous pro-
teins [1]. Degradation experiments performed in the present
study using fluorogenic substrates indicate that proteasomal
chymotrypsin-like activities and, to a lesser extent, caspase-
like activities are highly enhanced in homogenates from fi-
brosarcomas compared to healthy subcutis. These functional
results are in agreement with the observation that fibrosarco-
mas present a higher content of immunoproteasomes and
PA28. In fact, it has been reported that LMP7 substitution of the
constitutive subunit X results in stimulation of chymotrypsin-
like activity [44]. Moreover, PA28 is known to be a potent ac-
tivator of all three proteasomal peptidase activities, although
to different extents [7]. Finally, in agreement with the obser-
vation that LMP2 causes a reduction in caspase-like activity
[44], degradation of Z-YVAD-AMC in fibrosarcoma homoge-
nates is less enhanced compared to the degradation of the
substrate specific for chymotrypsin-like activity.
Taken together, our results indicate that, in neoplastic fi-
broblasts, differences in the composition of APM subunits
and the subsequent modifications of enzymatic activities
may result in the production of a characteristic spectrum of
peptides that is different from that produced by other cell
types and, specifically, in normal fibroblasts. Importantly, such
modifications might not be optimized for the generation and
presentation of tumor antigens that can elicit an effective
immune response based on the activation of specific anti–
tumor-associated antigen CD8+ lymphocytes. In fact, immu-
noproteasome expression, which causes a change in the type
of peptides processed and presented on certain allospecific-
ities, is indicated as a mechanism of tumor escape [19].
Accordingly, the hypothesis that immunoproteasomes are
always better suited for the processing of MHC class I–
restricted peptides has been challenged in recent years
following reports that some epitopes, mainly of self-origin,
are not processed by this form of proteasome and that mature
dendritic cells constitutively express immunoproteasomes
and, therefore, cannot efficiently present such antigenic pep-
tides [16,45]. The first examples of such epitopes that are
processed by standard proteasomes, but not by immunopro-
teasomes, are a peptide derived from a self-protein called
RU1 and a peptide derived from a melanoma differentiation
protein [16]. Successively, other melanoma antigens belong-
ing to the group of melanocyte differentiation antigens were
shown to be poorly generated by immunoproteasomes [17,
18]. Furthermore, it has been reported that several tumor-
specific antigens, melanoma differentiation antigens, and
antigens derived from ubiquitous self-proteins are recognized
less efficiently by specific CTL in cells treated with IFN-g [16,
18]. Although further studies are required to determine the
precise fraction of tumor epitopes that are poorly processed
by immunoproteasomes, the observation that proteasomal
Table 3. Immunohistochemical Evaluation of LAP, PA28a/b, LMP2, LMP7, X,










The number of positive cells was estimated semiquantitatively and scored as
() absence of immunoreaction; (+) 1% to 10% positive cells; (++) 11% to
50% positive cells; (+++) > 50% positive cells. Data refer to the immuno-
histochemical studies of two different animals.
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catalytic subunits induced by IFN-g are highly upregulated in
fibrosarcomas might be invoked as a mechanism to evade
immune surveillance in neoplastic fibroblasts. In fact, to the
best of our knowledge, this is the first time that a strong up-
regulation of LMPs and PA28s has been described in a
naturally occurring tumor. Interestingly, a proteasome switch
caused either by high local levels of cytokines and/or by
dysregulation of tumor cells might result in a lack of pre-
sentation of tumor antigens and escape from CTL attack.
Similarly to immunoproteasomes and PA28, another IFN-g–
induced APM component that is upregulated in FISS is LAP,
a cytosolic enzyme that can generate antigenic peptides from
longer proteasome products but also destroy them [9–12].
Although a recent report questions its role in the generation or
destruction of several antigenic peptides [46], previous stud-
ies have clearly identified in LAP the major cytosolic exopep-
tidase capable of trimming both N-extended precursors of
different antigenic peptides and mature epitopes [9,10] and
that overexpression of LAP results in a shorter half-life of
peptides in living cells [11]. Consequently, enhanced levels of
LAP in FISS might contribute to immune escape mechanism
by reducing the supply of antigens to MHC class I molecules.
Our findings have potentially important consequences to
cancer therapy. In fact, the observation that immunoprotea-
somes in a naturally occurring cancer are mainly expressed
gives rise to several concerns about anticancer treatments
based on systemic IFN-g therapy and could account for
observations of increased tumor progression after such
treatment [47,48]. In cancers that are similar to FISS and
present an enhanced expression of IFN-g–induced sub-
units, therapies aimed to reduce immunoproteasome levels
(e.g., treatment with neutralizing antibodies specific for IFN-g)
might have better a possibility to achieve positive results. Fur-
thermore, when designing cancer vaccines for these tumors,
priority should be given to epitopes that are well generated
by immunoproteasomes and that are highly abundant on the
surface of neoplastic cells.
Acknowledgements
We thank A. L. Goldberg, K. Tanaka, and T. Saric for pro-
viding antibodies.
References
[1] Goldberg AL, Cascio P, Saric T, and Rock KL (2002). The importance of
the proteasome and subsequent proteolytic steps in the generation of
antigenic peptides. Mol Immunol 39, 147–164.
[2] Anderton SM and Wraith DC (2002). Selection and fine-tuning of the
autoimmune T-cell repertoire. Nat Rev Immunol 2, 487–498.
[3] Dunn GP, Bruce AT, Ikeda H, Old LJ, and Schreiber RD (2002). Cancer
immunoediting: from immunosurveillance to tumor escape. Nat Immu-
nol 3, 991–998.
[4] Khong HT and Restifo NP (2002). Natural selection of tumor variants in
the generation of ‘‘tumor escape’’ phenotypes. Nat Immunol 3, 999–1005.
[5] Voges D, Zwickl P, and Baumeister W (1999). The 26S proteasome: a
molecular machine designed for controlled proteolysis. Annu Rev Bio-
chem 68, 1015–1068.
[6] Hershko A and Ciechanover A (1998). The ubiquitin system. Annu Rev
Biochem 67, 425–479.
[7] Rechsteiner M, Realini C, and Ustrell V (2000). The proteasome acti-
vator 11S REG (PA28) and class I antigen presentation. Biochem J 345,
1 –15.
[8] Harris CA, Hunte B, Krauss MR, Taylor A, and Epstein LB (1992).
Induction of leucine aminopeptidase by interferon-gamma. Identifica-
tion by protein microsequencing after purification by preparative two-
dimensional gel electrophoresis. J Biol Chem 267, 6865–6869.
[9] Beninga J, Rock KL, and Goldberg AL (1998). Interferon-gamma can stim-
ulate post-proteasomal trimming of the N terminus of an antigenic peptide
by inducing leucine aminopeptidase. J Biol Chem 273, 18734–18742.
[10] Mo XY, Cascio P, Lemerise K, Goldberg AL, and Rock KL (1999). Dis-
tinct proteolytic processes generate the C and N termini of MHC class
I –binding peptides. J Immunol 163, 5851–5859.
[11] Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P,
Janssen H, Calafat J, Drijfhout JW, and Neefjes J (2003). Peptide diffu-
sion, protection, and degradation in nuclear and cytoplasmic compart-
ments before antigen presentation by MHC class I. Immunity 18, 97–108.
[12] Saric T, Graef CI, and Goldberg AL (2004). Pathway for degradation of
peptides generated by proteasomes: a key role for thimet oligopepti-
dase and other metallopeptidases. J Biol Chem 279, 46723–46732.
[13] Cascio P, Hilton C, Kisselev AF, Rock KL, and Goldberg AL (2001). 26S
Proteasomes and immunoproteasomes produce mainly N-extended
versions of an antigenic peptide. EMBO J 20, 2357–2366.
[14] Rock KL, York IA, and Goldberg AL (2004). Post-proteasomal antigen
processing for major histocompatibility complex class I presentation.
Nat Immunol 5, 670–677.
[15] Cascio P, Call M, Petre BM, Walz T, and Goldberg AL (2002). Properties
of the hybrid form of the 26S proteasome containing both 19S and PA28
complexes. EMBO J 21, 2636–2645.
[16] Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M,
Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T,
et al. (2000). Processing of some antigens by the standard proteasome
but not by the immunoproteasome results in poor presentation by den-
dritic cells. Immunity 12, 107–117.
[17] Van den Eynde BJ and Morel S (2001). Differential processing of class-
I – restricted epitopes by the standard proteasome and the immunopro-
teasome. Curr Opin Immunol 13, 147–153.
[18] Chapiro J, Claverol S, Piette F, Ma W, Stroobant V, Guillaume B, Gairin
JE, Morel S, Burlet-Schiltz O, Monsarrat B, et al. (2006). Destructive
cleavage of antigenic peptides either by the immunoproteasome or by
the standard proteasome results in differential antigen presentation. J
Immunol 176, 1053–1061.
[19] Chang CC and Ferrone S (2007). Immune selective pressure and HLA
class I antigen defects in malignant lesions. Cancer Immunol Immu-
nother 56, 227–236.
[20] Seliger B, Maeurer MJ, and Ferrone S (2000). Antigen-processing ma-
chinery breakdown and tumor growth. Immunol Today 21, 455–464.
[21] Seliger B, Wollscheid U, Momburg F, Blankenstein T, and Huber C
(2000). Coordinate downregulation of multiple MHC class I antigen pro-
cessing genes in chemical-induced murine tumor cell lines of distinct
origin. Tissue Antigens 56, 327–336.
[22] Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, and Seliger B
(2001). Deficient expression of components of the MHC class I antigen
processing machinery in human cervical carcinoma. Int J Oncol 19,
1211–1220.
[23] Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, and Storkel S
(2003). Characterization of human lymphocyte antigen class I antigen-
processing machinery defects in renal cell carcinoma lesions with
special emphasis on transporter-associated with antigen-processing
down-regulation. Clin Cancer Res 9, 1721–1727.
[24] Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer
F, Storkel S, and Seliger B (2004). MHC class I antigen processing
pathway defects, ras mutations and disease stage in colorectal carci-
noma. Int J Cancer 109, 265–273.
[25] Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, and
Seliger B (2004). HER-2/neu–mediated regulation of components of the
MHC class I antigen-processing pathway. Cancer Res 64, 215–220.
[26] Meissner M, Reichert TE, Kunkel M, Gooding W,Whiteside TL, Ferrone S,
and Seliger B (2005). Defects in the human leukocyte antigen class I
antigen processing machinery in head and neck squamous cell carci-
noma: association with clinical outcome. Clin Cancer Res 11, 2552–2560.
[27] Hendrick MJ, Goldschmidt MH, Shofer FS, Wang YY, and Somlyo AP
(1992). Postvaccinal sarcomas in the cat: epidemiology and electron probe
microanalytical identification of aluminum. Cancer Res 52, 5391–5394.
[28] Goldschmidt MH and Henrick MJ (2002). Tumors of the skin and soft
tissues. In Meuten, DJ (Ed.), Tumors in Domestic Animals, 4th ed, Iowa
State Press, Ames, IA, USA pp. 85–86.
[29] Vail DM and MacEwen EG (2000). Spontaneously occurring tumors of
968 MHC Class I APM Alterations in Cancer Cerruti et al.
Neoplasia . Vol. 9, No. 11, 2007
companion animals as models for human cancer. Cancer Invest 18,
781–792.
[30] McNiel EA (2001). Vaccine-associated sarcomas in cats: a unique can-
cer model. Clin Orthop Relat Res 382, 21–27.
[31] Owen L (1980). TNM Classification of Tumors in Domestic Animals
World Health Organization, Geneva.
[32] Ferrone S, Finerty JF, Jaffee EM, and Nabel GJ (2000). How much longer
will tumour cells fool the immune system? Immunol Today 21, 70–72.
[33] Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M,
Duggan-Keen M, and Stern PL (1997). Implications for immunosurveil-
lance of altered HLA class I phenotypes in human tumours. Immunol
Today 18, 89–95.
[34] Marincola FM, Jaffee EM, Hicklin DJ, and Ferrone S (2000). Escape of
human solid tumors from T-cell recognition: molecular mechanisms and
functional significance. Adv Immunol 74, 181–273.
[35] Groettrup M, Standera S, Stohwasser R, and Kloetzel PM (1997). The
subunits MECL-1 and LMP2 are mutually required for incorporation into
the 20S proteasome. Proc Natl Acad Sci USA 94, 8970–8975.
[36] Nandi D, Woodward E, Ginsburg DB, and Monaco JJ (1997). Intermedi-
ates in the formation of mouse 20S proteasomes: implications for the
assembly of precursor beta subunits. EMBO J 16, 5363–5375.
[37] Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, and
Colbert RA (1998). Immunoproteasome assembly: cooperative incor-
poration of interferon gamma (IFN-gamma)– inducible subunits. J Exp
Med 187, 97–104.
[38] Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, and Ting
JP (1997). Induction of MHC class I expression by the MHC class II
transactivator CIITA. Immunity 6, 591–600.
[39] Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, Sheiman LA, and Liu Y
(1998). Proto-oncogene PML controls genes devoted to MHC class I
antigen presentation. Nature 396, 373–376.
[40] Macy DW and Hendrick MJ (1996). The potential role of inflammation in
the development of postvaccinal sarcomas in cats. Vet Clin North Am
Small Anim Pract 26, 103–109.
[41] Akiyama K, Yokota K, Kagawa S, Shimbara N, Tamura T, Akioka H,
Nothwang HG, Noda C, Tanaka K, and Ichihara A (1994). cDNA cloning
and interferon gamma down-regulation of proteasomal subunits X and
Y. Science 265, 1231–1234.
[42] Stohwasser R, Standera S, Peters I, Kloetzel PM, and Groettrup M
(1997). Molecular cloning of the mouse proteasome subunits MC14 and
MECL-1: reciprocally regulated tissue expression of interferon-gamma–
modulated proteasome subunits. Eur J Immunol 27, 1182–1187.
[43] Singh S, Awasthi N, Egwuagu CE, and Wagner BJ (2002). Immunopro-
teasome expression in a nonimmune tissue, the ocular lens. Arch Bio-
chem Biophys 405, 147–153.
[44] Gaczynska M, Rock KL, Spies T, and Goldberg AL (1994). Peptidase
activities of proteasomes are differentially regulated by the MHC-encoded
genes LMP2 and LMP7. Proc Natl Acad Sci USA 91, 9212–9217.
[45] Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, and
Groettrup M (1999). Dendritic cells up-regulate immunoproteasomes
and the proteasome regulator PA28 during maturation. Eur J Immunol
29, 4037–4042.
[46] Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM,
Yancopoulos GD, Neefjes JJ, and Rock KL (2005). Leucine aminopepti-
dase is not essential for trimming peptides in the cytosol or generating
epitopes for MHC class I antigen presentation. J Immunol 175, 6605–6614.
[47] Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe
H, Crowley J, and Coltman C (1990). Recombinant human interferon
gamma: adverse effects in high-risk stage I and II cutaneous malignant
melanoma. J Natl Cancer Inst 82, 1071.
[48] Kowalzick L, Weyer U, Lange P, and Breitbart EW (1990). Systemic
therapy of advanced metastatic malignant melanoma with a combina-
tion of fibroblast interferon-beta and recombinant interferon-gamma.
Dermatologica 181, 298–303.
MHC Class I APM Alterations in Cancer Cerruti et al. 969
Neoplasia . Vol. 9, No. 11, 2007
